TrustInSoft commercializes a source code analyzer called TrustInSoft Analyzer, which analyzes C and C++ code and mathematically guarantees the absence of defects, immunity of software components to the most common security flaws, and compliance with a specification. The technology is recognized by U.S. federal agency the National Institute of Standards and Technology (NIST), and was the first in the world to meet NIST’s SATE V Ockham Criteria for high quality software.
The key differentiator for TrustInSoft Analyzer is its use of mathematical approaches called formal methods, which allow for an exhaustive analysis to find all the vulnerabilities or runtime errors and only raises true alarms.
Companies who use TrustInSoft Analyzer reduce their verification costs by 4, efforts in bug detection by 40, and obtain an irrefutable proof that their software is safe and secure.
The experts at TrustInSoft can also assist clients in training, support and additional services.
Learn more
Jama Connect®, a product development platform, uniquely creates Living Requirements™. This digital thread is created through siloed, test, and risk activities to provide end to end compliance, risk mitigation, process improvement, and compliance. Companies creating complex products, systems, and software can now define, align, and execute on what they need. This reduces the time and effort required to prove compliance and saves on rework. You can be sure of success by choosing a solution that is easy-to-use, flexible, and offers support and services that are adoption-oriented.
Learn more
Genedata Biologics
Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.
Learn more
Gritstone
The foundational aspect of our immunotherapy approach lies in our comprehension of antigens and neoantigens, particularly in identifying which variations will be transcribed, translated, processed, and subsequently displayed on the surface of cells via Human leukocyte antigen (HLA) molecules, thus making them recognizable to T cells. We achieve this by employing Gritstone EDGETM, a unique platform powered by machine learning. Creating cancer immunotherapies that incorporate tumor-specific neoantigens proves challenging, mainly because tumors consist of numerous mutations, yet only a fraction of these lead to genuine tumor-specific neoantigens. To tackle this complexity, we have developed EDGE's cutting-edge integrated neural network model, trained with millions of data points gathered from a diverse range of tumor and normal tissue samples across various patient ancestries. This extensive training allows us to enhance the accuracy of neoantigen identification and improve the effectiveness of our immunotherapy strategies.
Learn more
